Cadila Healthcare has informed that it has enclosed a copy of press release dated November 12, 2020 titled ‘Zydus successfully completes Phase II clinical trials with Pegylated Interferon alpha-2b in India; the Company to start Phase III clinical trials’. The contents of the press release give full details. Bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.
The above information is a part of company’s filings submitted to BSE.